Morgan Stanley sets $40 target on Kyverna Therapeutics shares By Investing.com
© Reuters. On Monday, Morgan Stanley initiated coverage on Kyverna Therapeutics Inc (NASDAQ:KYTX), a biopharmaceutical company, with an Overweight rating ...
© Reuters. On Monday, Morgan Stanley initiated coverage on Kyverna Therapeutics Inc (NASDAQ:KYTX), a biopharmaceutical company, with an Overweight rating ...
DariaRen Kyverna Therapeutics (KYTX) has upsized its proposed initial public offering to $200M from $100M. According to a recent SEC ...
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.
© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.